×
About 2,803 results

ALLMedicine™ Angiosarcoma Center

Research & Reviews  995 results

Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with An...
https://doi.org/10.1093/oncolo/oyac155
The Oncologist; Riedel RF, Chua V et. al.

Aug 4th, 2022 - NC-6300 is a novel epirubicin (EPI) drug conjugated polymeric micelle developed using cutting-edge micellar nanoparticle technology. The nanoparticle epirubicin conjugates EPI to a polymer via a pH-sensitive linker which enables the selective EPI ...

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
https://clinicaltrials.gov/ct2/show/NCT05026736

Aug 2nd, 2022 - PRIMARY OBJECTIVE: I. To evaluate the efficacy of sintilimab in subjects with angiosarcoma (progression- free rate PFR at 9 cycles by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1). SECONDARY OBJECTIVE: I. To evaluate the objective res...

Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
https://clinicaltrials.gov/ct2/show/NCT04339738

Aug 2nd, 2022 - PRIMARY OBJECTIVES: I. To determine the progression free survival (PFS) for paclitaxel with and without nivolumab in subjects with taxane naive angiosarcoma. II. To determine the overall response rate (ORR) of nivolumab in combination with cabozan...

A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
https://clinicaltrials.gov/ct2/show/NCT03544567

Aug 1st, 2022 - Oraxol will be administered once daily for 3 consecutive days every week during the Treatment Period from Weeks 1 through 25. Subjects who do not have documented disease progression by the end of the Treatment Period will be eligible to receive th...

A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma
https://clinicaltrials.gov/ct2/show/NCT04996004

Jul 28th, 2022 - This trial will be conducted in 2 phases: Phase I (Dose Escalation of TTI-621 in combination with doxorubicin) and Phase II (Dose Expansion of TTI-621 in combination with doxorubicin). Phase I (Dose Escalation of TTI-621 in combination with doxoru...

see more →

Clinicaltrials.gov  37 results

Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
https://clinicaltrials.gov/ct2/show/NCT04339738

Aug 2nd, 2022 - PRIMARY OBJECTIVES: I. To determine the progression free survival (PFS) for paclitaxel with and without nivolumab in subjects with taxane naive angiosarcoma. II. To determine the overall response rate (ORR) of nivolumab in combination with cabozan...

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
https://clinicaltrials.gov/ct2/show/NCT05026736

Aug 2nd, 2022 - PRIMARY OBJECTIVE: I. To evaluate the efficacy of sintilimab in subjects with angiosarcoma (progression- free rate PFR at 9 cycles by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1). SECONDARY OBJECTIVE: I. To evaluate the objective res...

A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
https://clinicaltrials.gov/ct2/show/NCT03544567

Aug 1st, 2022 - Oraxol will be administered once daily for 3 consecutive days every week during the Treatment Period from Weeks 1 through 25. Subjects who do not have documented disease progression by the end of the Treatment Period will be eligible to receive th...

A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma
https://clinicaltrials.gov/ct2/show/NCT04996004

Jul 28th, 2022 - This trial will be conducted in 2 phases: Phase I (Dose Escalation of TTI-621 in combination with doxorubicin) and Phase II (Dose Expansion of TTI-621 in combination with doxorubicin). Phase I (Dose Escalation of TTI-621 in combination with doxoru...

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
https://clinicaltrials.gov/ct2/show/NCT03860272

Jul 26th, 2022 - This Phase 1 study will enroll up to approximately 195 evaluable adult participants with refractory cancer (solid tumors) regardless of diagnosis. The study will consist of a 3+3 dose escalation. Different dose levels of botensilimab, both monothe...

see more →

News  82 results

Painless Vulvar Nodule
https://www.mdedge.com/dermatology/article/255414/dermatopathology/painless-vulvar-nodule
V. Claire Vaughan, MD, Miriam D. Post, MD

Jun 14th, 2022 - The Diagnosis: Proximal-Type Epithelioid Sarcoma Proximal-type epithelioid sarcoma (PES) is a rare high-grade sarcoma of uncertain histogenesis that may present with a benign clinical appearance. Proximal-type epithelioid sarcoma peaks at 20 to 40.

Meyer Characterizes Current Approaches to Diagnosing, Managing, and Studying Cardiac Angiosarcoma
https://www.onclive.com/view/meyer-characterizes-current-approaches-to-diagnosing-managing-and-studying-cardiac-angiosarcoma

Jan 10th, 2022 - Welcome to OncLiveOn Air®! I’m your host today, Jason Harris. OncLiveOn Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and prin...

Key Advances in Sarcoma Lead to More Personalized Medicine Efforts
https://www.onclive.com/view/key-advances-in-sarcoma-lead-to-more-personalized-medicine-efforts

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more personalized for patients...

Schwartz Hunts for Predictive Biomarkers in Soft Tissue Sarcoma
https://www.onclive.com/view/schwartz-hunts-for-predictive-biomarkers-in-soft-tissue-sarcoma

Oct 6th, 2021 - Although several research efforts have been dedicated to evaluating the use of immunotherapy in patients with soft tissue sarcomas, such as angiosarcoma and gastrointestinal stromal tumor (GIST), the hunt for predictive biomarkers for response to ...

Agminated Nodules on the Scalp
https://www.mdedge.com/dermatology/article/242926/dermatopathology/agminated-nodules-scalp
Lan Zhang, MD, Yang Yang, MD et. al.

Jul 14th, 2021 - The Diagnosis: Cutaneous Angiosarcoma Biopsy revealed a cellular neoplasm consisting of atypical polygonal cells with a hobnailed appearance, vasoformative characteristics, and rare extravasated erythrocytes. The tumor had an infiltrative growth p.

see more →

Patient Education  7 results see all →